Skip to main content
Sign In
 

Infectious Diseases - Research Funding


 

(listed alphabetically by Principal Investigator or by Section faculty member involved)

International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Principal Investigator: Mark J. Abzug, MD
Source: NICHD, NIH - BRS-IMPCT-Q-06-00116-T00
Amount: $2,450/yr
Term: 2006 - 2007

NIH Collaborative Antiviral Study Group: A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enterovirus Sepsis Syndrome
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-A1-30025
Amount: Per patient enrolled
Term: 1999 - ongoing

NIH Collaborative Antiviral Study Group: A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir for the Treatment of Children <24 Months of Age with Confirmed Influenza Infection
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: Per patient enrolled
Term: 2007 - ongoing

NIH Collaborative Antiviral Study Group: Phase 3 Randomized, Placebo-Controlled Blinded Investigation of 6 Weeks vs. 6 Months of Oral Valganciclovir in Infants with Symptomatic Congenital Cytomegalovirus Infection
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: Per patient enrolled
Term: 2007 - ongoing

NIH Collaborative Antiviral Study Group: Retrospective Chart Review to Assess the Safety of Oseltamivir Compared to Alternate Antiviral Therapy Administered to Children Less than 12 Months of Age
Principal Investigator: Mark J. Abzug, MD
Source: NIAID, NIH - N01-AI-30025
Amount: $1720
Term: 2006 - 2008

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme)
Principal Investigator: Kenny Chan, MD
Co-Investigator: Mark J. Abzug, MD
Source: Genentech, Inc.
Amount: Per patient enrolled
Term: 2006 - ongoing

Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multicenter Study of Outpatient Therapy and Evaluation of Genomic and Proteomic Correlates
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: St. Baldrick's Foundation Grant
Amount: $18,600/yr
Term: 2006 - 2008

Fever and Neutropenia in Pediatric Oncology Patients: A Randomized, Controlled, Multicenter Study of Outpatient Therapy and Evaluation of Genomic and Proteomic Correlates
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: Pediatric Clinical Translational Research Center Pilot and Feasibility Program Grant
Amount: $19,880/yr
Term: 2006 - 2008

Hematology Oncology Fellowship Program Grant: Fever and Neutropenia in Pediatric Oncology Patients
Principal Investigator: Sue Lindemulder, MD
Consultant: Mark J. Abzug, MD
Source: Amgen Inc.
Amount: $40,000/yr
Term: 2006 - 2007

Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient enrolled
Term: 2001 - 2007

Phase III, Open-Label, Randomized, Multicenter Study to Evaluate Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine Administered with Routine Infant Vaccinations (Infants)
Principal Investigator: Marsha S. Anderson, MD
Co-Principal Investigator: Mary P. Glodé, MD
Source: Novartis AG
Amount: Per patient enrolled
Term: 2007 - 2009

Phase III Randomized, Multicenter Study to Evaluate Lot-to-Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine and to Evaluate Safety and Immunogenicity in Adolescents 11-18 Years
Principal Investigator: Marsha S. Anderson, MD
Co-Principal Investigator: Mary P. Glodé, MD
Source: Novartis AG
Amount: Per patient enrolled
Term: 2007 - 2009

Region VIII Center for Excellence for Biodefense and Emerging Infectious Diseases: Education and Outreach Subproject
Principal Investigator (Subproject): Marsha S. Anderson, MD
Co-Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: NIAID, NIH - U54-AI-065357
Amount: $434,404
Term: 2005 - 2009

Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2007 - 2008

Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Consultant: Mark J. Abzug, MD
Source: NIAID, NIH - 1K08AI073525-01A1
Amount: $122,500/yr
Term: 2008 - 2013

Mentored Clinical Scientist Research Career Development Award: Epidemiology and Pathogenesis of Novel Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: NIAID, NIH - 1 K08 AI073525-01A1
Amount: $132,220/yr
Term: 2008 - 2013

Pediatric Infectious Disease Society Fellowship Award: Virus Entry and Clinical Significance of the Newly Discovered Human Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: Roche Laboratories - CoV-NL63
Amount: $30,000/yr
Term: 2005 - 2007

Specialized Biodefense Training Clinical/Translational: Epidemiology and Characterization of Novel Rocky Mountain Bat Coronaviruses
Principal Investigator: Samuel R. Dominguez, MD, PhD
Source: NIAID, NIH - U54-AIO65367
Amount: $117,170/yr
Term: 2007 - 2008

Phase III Open-label, Nonrandomized International Multicenter Trial to Evaluate Efficacy and Safety of Cardiolite Myocardial Perfusion and Imaging in Pediatric Subjects with Kawasaki Disease
Principal Investigator: Mary P. Glodé, MD
Source: Bristol-Myers Squibb
Amount: Per patient enrolled
Term: 2006 - 2016

Atopic Dermatitis and Vaccinia Immunization Network
Principal Investigator: Myron J. Levin, MD
Source: National Jewish Health, NIAID, NIH - HHSN266200400029C
Amount: $105,092
Term: 2004 - 2008

A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of bD-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: St. Louis University/GlaxoSmithKline, NIAID, NIH - N01-AI-45250
Amount: $1,942,420
Term: 2002 - 2011

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Principal Investigator: Myron J. Levin, MD
Source: Social and Scientific Systems (SSS), NIAID, NIH - BRS-Q-06-00116-T002
Amount: $109,916
Term: 2006 - 2013

International Pediatric and Perinatal HIV Studies Network
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Adriana Weinberg, MD, Mark J. Abzug, MD, Robin E. McEvoy, PhD, Suzanne M. Paul, BSN, FNP-C, and Amy Witte, RN, MSN, FNP-C
Source: Westat, NICHD, NIH - N01-HD-3-3345
Amount: $7,008,031
Term: 2002 - 2007

Monitor Subjects Who Originally Received Herpes Zoster Vaccine to Monitor the Durability of the Vaccine
Principal Investigator: Myron J. Levin, MD
Source: Veteran Administration Connecticut Research & Education Foundation (VACREF), Merck - CSP 403C
Amount: $752,088
Term: 2005 - 2010

A Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Patient-Initiated Famiciclovir 1000 mg b.i.d. x 1 day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults with Recurrent Genital Herpes
Principal Investigator: Myron J. Levin, MD
Source: Novartis AG - CFAM810A-A2308
Amount: $94,544
Term: 2006 - 2010

NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Mark J. Abzug, MD
Source: Westat, NICHD, NIH - N01-DK-8-0001
Amount: $1,312,107
Term: 2007 - 2012

NICHD International and Domestic Pediatric and Maternal HIV Studies Coordinating Center
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Adriana Weinberg, MD, Mark J. Abzug, MD, Emily A. Barr, CPNP, CNM, Robin E. McEvoy, PhD, Suzanne M. Paul, BSN, FNP-C, and Amy Witte, RN, MSN, FNP-C
Source: Westat, NICHD, NIDDK, NIH - N01-DK-8-0001
Amount: $7,315,975
Term 2007 - 2012

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V21/Heat-Treated Varicella-Zoster Virus (ZVZ) Vaccine in Immumncompromised Adults
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $131,784
Term: 2007 - 2009

A Phase I/II, Double-Blind, Randomized, Controlled, Dose-Range Study to Assess the Safety/Immunogenicity of an HPV-16/18/31/45 VLP/AS04 Vaccine when Administered Intramuscularly
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 102115
Amount: $82,550
Term: 2005 - 2009

A Phase II, Dose-Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes
Principal Investigator: Myron J. Levin, MD
Source: Astellas Pharma U.S., Inc. - 200705-280
Amount: $225,321
Term: 2007 - 2011

A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety, and Tolerability of ZOSTAVAX in Subjects 50 to 59 Years of Age, V211-022
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $175,015
Term: 2007 - 2010

A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Subjects with a History of Herpes Zoster
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc. - V211-014
Amount: $16,198
Term: 2006 - 2009

A Phase III, Double-Blind, Randomized, Controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of Glaxo-Smith Kline Biologicals’ HPV-26/28 L1/AS04 Vaccine Administered Intramuscularly
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - 104820
Amount: $66,750
Term: 2006 - 2009

A Phase IIIB, Observer-Blind, Randomized, Multicenter Study with Two Parallel Groups to Compare the Immunogenicity of GSK Biologicals HPV-16/18 L1/AS04 Versus Merck’s Gardasil(R) Vaccine when Administered Intramuscularly According to a 3-Dose Schedule in Healthy Adult Females 18-45 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline - HPV108933/010
Amount: $86,813
Term: 2007 - 2010

A Randomized, Double-Blind, Active-Controlled, Vehicle-Controlled, Subject-Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis
Principal Investigator: Myron J. Levin, MD
Source: Medivir - ME 609
Amount: $86,730
Term: 2006 - 2009

Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories, Merck & Co., Inc.
Amount: $69,000
Term: 2003 - 2006

Ryan White Part D HIV Program for Children, Youth, Women, and Families
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Investigator: Adriana Weinberg, MD
Source: Maternal and Child Health Bureau, HRSA, HHS, - H12HA00070
Amount: $885,272/yr
Term: 2004 - 2007

Ryan White Part D HIV Program for Children, Youth, Women, and Families
Principal Investigator: Myron J. Levin, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Investigator: Adriana Weinberg, MD
Source: Maternal and Child Health Bureau, HRSA, HHS - H12HA00070
Amount: $936,325/yr
Term: 2007 - 2012

University of Colorado Center for AIDS Research
Principal Investigator: Thomas Campbell, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: NIAID, NIH - P30 AI054907
Amount: $7,946,900
Term: 2003 - 2008

Comprehensive Resources and Counseling Services for People with HIV
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $63,074/yr
Term: 2007 - 2009

Evaluation of Programmed Cell Death-1 (PD-1) Expression and Multifunctional HIV-Specific T Lymphocytes in Infants and Children with HIV Infection
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Center for AIDS Research (CFAR) Developmental Projects
Amount: $25,000/yr
Term: 2007 - 2009

Implementation of Rapid HIV Testing at Denver Metro Labor and Delivery Sites
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $100,231
Term: 2007 - 2009

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT)
Principal Investigator: Elizabeth J. McFarland, MD
Source: Social and Scientific Systems (SSS), NIAID, NIH - BRS-Q-06-00116-T001
Amount: $71,381
Term: 2006 - 2013

Pediatric HIV/AIDS Cohort Study (AMP Study)
Principal Investigator: Elizabeth J. McFarland, MD
Source: NICHD, NIH, Harvard - U01-HD052102
Amount: $390,000
Term: 2008 - 2010

Pediatric HIV/AIDS Cohort Study (PHACS) Clinical Site (SMARTT Study)
Principal Investigator: Elizabeth J. McFarland, MD
Co-Investigators: Emily A. Barr, CPNP, CNM, and Robin E. McEvoy, PhD
Source: NICHD, NIH, Harvard - U01-HD052102
Amount: $1,150,000
Term: 2006 - 2010

Ryan White Part A: Funds for HIV Care: Outpatient Ambulatory Medical Care and Pharmaceutical Assistance and Mental Health
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources, HRSA, Ryan White Part A
Amount: $236,794
Term: 2008 - 2009

Ryan White Part B: First Care/Retention in Care
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $84,000
Term: 2007 - 2009

Ryan White Part B: HIV Supplemental Funding for Medical Care and Behavioral Health and Psychosocial Support
Principal Investigator: Elizabeth J. McFarland, MD
Source: Colorado Department of Public Health and Environment
Amount: $109,439
Term: 2009 - 2010

Ryan White Title I Funds for HIV Care: Primary Health Care and Drug Reimbursement
Principal Investigator: Elizabeth J. McFarland, MD
Source: Mayor's Office of HIV Resources, HRSA Ryan White Title 1
Amount: $274,347
Term: 2006 - 2008

Center for AIDS Research Pharmacy Supplement
Principal Investigator: Courtney Fletcher, PharmD
Co-Investigator: Elizabeth J. McFarland, MD
Source: NIAID, NIH - 5P30 AI054907-04
Amount: $350,002
Term: 2004 - 2007

Impact of Exclusive vs. Mixed Breast Feeding on Susceptibility of Infants to HIV Infection
Principal Investigator: Edward Janoff, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Elizabeth Glaser Pediatric AIDS Foundation
Amount: $200,000
Term: 2008 - 2010

Idiopathic Thrombocytopenic Purpura (ITP) After Live Virus and Influenza Vaccines: A Multicenter Retrospective Cohort Study
Principal Investigator: Jason Glanz, PhD
Co-Principal Investigator: Sean O’Leary, MD
Source: FDA
Amount: $1,041,000
Term: 2008 - 2010

Construction and Phenotypic Assessment of Mycobacterial Phospholipase A Deletion Mutants
Principal Investigator: Sarah K. Parker, MD
Source: Potts Memorial Foundation - 200709-039
Amount: $32,000
Term: 2007 - 2008

Construction and Phenotypic Assessment of Mycobacterial Phospholipase A Deletion Mutants
Principal Investigator: Sarah K. Parker, MD
Source: TCH Research Institute
Amount: $70,000/yr
Term: 2007 - 2009

Investigation of Mycobacterium Tuberculosis Phospholipase A Cell Wall Activity
Principal Investigator: Sarah K. Parker, MD
Source: American Lung Association
Amount: $40,000/yr
Term: 2008 - 2010

Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: NIAID, NIH - 5 K08 AI050646-05
Amount: $125,280
Term: 2002 - 2008

Determination of Sensitive Methods for Detecting Respiratory Virus Infections in Respiratory Tract Secretions
Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: Bill & Melinda Gates Foundation - 2581081
Amount: $265,977
Term: 2008 - 2010

Pneumo-Accelerated Development and Introduction Plan (ADIP)
Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: Johns Hopkins University - 2580754
Amount: $25,000
Term: 2005 - 2009

Zoonotic Avian Influenza: The Human-Animal Interface in the U.S. and Asia
Co-Principal Investigator: Eric A. Simões, MB, BS, DCH, MD
Source: CDC - 2580805
Amount: $485,000/yr
Term: 2006 - 2009

Atopic Dermatitis and Vaccinia Network (ADVN) Biomarker Registry Study
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH - N01-AI-40029
Amount: $80,711/yr
Term: 2007 - 2009

Critical Aspects of Successful Management of HIV Infection During Pregnancy
Principal Investigator: Adriana Weinberg, MD
Source: Abbott Laboratories - IIS-USAV-05-020
Amount: $35,973
Term: 2005 - 2009

Dendritic Cell Co-Infection with HIV and CMV
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH, and Colorado Center for AIDS Research - 5P30 AI054907
Amount: $25,000/yr
Term: 2007 - 2008

HSV Susceptibility to ASP2151
Principal Investigator: Adriana Weinberg, MD
Source: Astellas Pharma US, Inc.
Amount: $782,135
Term: 2007 - 2009

Incidence of hMPV in Lung Transplant Recipients
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc. - SYN092-04d
Amount: $39,279
Term: 2005 - 2009

Influenza A and B Respiratory Specimens Acquisition
Principal Investigator: Adriana Weinberg, MD
Source: BD Diagnostics, Inc.
Amount: $40,413
Term: 2007 - 2010

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT):
Immunology Core Laboratory

Principal Investigator: Adriana Weinberg, MD
Co-Principal Investigator: Elizabeth J. McFarland, MD
Source: NICHD, NIH - N01-HD-33162
Amount: $300,000/yr
Term: 2007 - 2012

Kinetics of Viral Shedding and Immunologic Responses to the Cold-Adapted Influenza Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc. - CAIV-T
Amount: $135,645
Term: 2006 - 2009

Mechanisms of Protection of Varicella-Zoster Virus Infection Against Glioblastoma
Principal Investigator: Adriana Weinberg, MD
Source: National Cancer Institute, NIH - P30 CA046934
Amount: $20,000/yr
Term: 2008 - 2009

Reconstitution of Protective CMV Immunity and Immune Regulation After HAART
Principal Investigator: Adriana Weinberg, MD
Source: NIAID, NIH - 1R21AI073121-01A2
Amount: $125,000/yr
Term: 2007 - 2009

RSV and PIV Immunology Pilot
Principal Investigator: Adriana Weinberg, MD
Source: MedImmune, Inc.
Amount: $187,562/yr
Term: 2005 - 2009

Type 1 Diabetes TrialNet Study
Principal Investigator: Adriana Weinberg, MD
Source: NIDDK, NIH - U01 DK61055
Amount: $385,750/yr
Term: 2003 - 2012

Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Cancer Institute, NIH - R01 CA52689
Amount: $14,009/yr
Term: 1997 - 2012

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (VP63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)
Principal Investigator: Mark J. Abzug, MD
Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group, National Institutes of Health
Amount: Per patient enrolled
Term: 1999-ongoing

Region VIII Center for Excellence for Biodefense and Emerging Infectious Diseases: Education and Outreach Subproject
Principal Investigator (Subproject): Marsha S. Anderson, MD
Source: National Institutes of Health
Amount: $688,953
Term: 2005-2009

Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient
Term: 2001-present

Apoptotic Signaling in Viral Myocarditis
Principal Investigator: Roberta L. DeBiasi, MD
Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01
Amount: $604,800
Term: 2002-2007

A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of Bd-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who Are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease and St. Louis University/GlaxoSmithKline
Amount: $974,693/yr
Term: 2002-2006

University of Colorado Center for AIDS Research
Principal Investigator: Robert Schooley, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $7,946,900
Term: 2003-2008

Study of the Safety and Efficacy of an Iontophoretic Device to Treat Recurrent Herpes Labialis
Principal Investigator: Myron J. Levin, MD
Source: Klearsen Corporation
Amount: $7,946,900
Term: 2003-2005

Pediatric and Perinatal HIV Clinical Trials
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat and National Institutes of Health, National Institute of Child and Human Development - N01-HD-3-3162
Amount: $5,010,161
Term: 2002-2007

Expansion of Pediatric ACTU
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - U0132915-05
Amount: $4,156,500
Term: 1996-2007

Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories
Amount: $69,000
Term: 2003-2006

Rocky Mountain Regional Center for Excellence Clinical Training Grant
Principal Investigator: Ann-Christine Nyquist, MD, MSPH
Source: National Institutes of Health
Amount: $492,535
Term: 2005-2009

Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: National Institutes of Health - 1 K08 AI050646-04
Amount: $560,000
Term: 2002-2007

CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R01 A140870-05
Amount: $673,622
Term: 2002-2005

Immune Responses to Varicella Vaccine in HIV-Infected Adults
Principal Investigator: Kathleen Brady, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - K23RR16116-02
Amount: $754,246
Term: 2000-2005

Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - R01 CA52689
Amount: $8,000,863
Term: 2001-2006

A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril (VP63843) in the Treatment of Neonates with EV Sepsis Syndrome (Protocol Version 2.0/Version Date 4/25/99)
Principal Investigator: Mark J. Abzug, MD
Source: National Institute of Allergy and Infectious Disease Collaborative Antiviral Study Group, National Institutes of Health
Amount: Per patient enrolled
Term: 1999-ongoing

Safety of Ciprofloxacin in Pediatric Patients
Principal Investigator: Marsha S. Anderson, MD
Source: Bayer Corporation
Amount: Per patient
Term: 2001-present

Denver for Advanced Public Health Preparedness Center
Principal Investigator: Arthur Davidson, MD
Co-Investigator: Marsha S. Anderson, MD
Source: Centers for Disease Control and Prevention - U90/CCU817608
Amount: $12,000
Term: 2000-2003

Apoptotic Signaling in Viral Myocarditis
Principal Investigator: Roberta L. DeBiasi, MD
Source: National Institutes of Health Physician Scientist Award - 1 K08 A152261-01
Amount: $604,800
Term: 2002-2007

Effectiveness of Pneumococcal Conjugate Vaccine in Children
Co-Principal Investigators: Mary P. Glodé, MD, and Ann-Christine Nyquist, MD, MSPH
Source: Centers for Disease Control and Prevention - 2890
Amount: $419,460
Term: 2000-2004

Pertussis Vaccine Effectiveness Study Among Children Aged 6 to 59 Months
Co-Principal Investigators: Mary P. Glodé, MD, and Christine Robinson, PhD
Source: Centers for Disease Control and Prevention - 98B066(N)
Amount: $148,300
Term: 1998-2003

A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of Bd-Alum/MPL Vaccine in the Prevention of Genital Herpes Diseases in Young Women Who Are HSV-1 and -2 Seronegative
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease and St. Louis University/GlaxoSmithKline
Amount: $974,693/yr
Term: 2002-2006

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Pilot Study to Assess the Safety of Live, Attenuated Varicella-Zoster Vaccine Given Concomitantly with Recombinant Human Interleukin-12 (rhIL-12) in Healthy Adults 60 to 79 Years of Age
Principal Investigator: Myron J. Levin, MD
Source: Genetics Institute
Amount: $9,126,000
Term: 1999-2004

University of Colorado Center for AIDS Research
Principal Investigator: Robert Schooley, MD
Co-Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease
Amount: $7,946,900
Term: 2003-2008

Study of the Safety and Efficacy of an Iontophoretic Device to Treat Recurrent Herpes Labialis
Principal Investigator: Myron J. Levin, MD
Source: Klearsen Corporation
Amount: $7,946,900
Term: 2003-2005

Pediatric and Perinatal HIV Clinical Trials
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Westat and National Institutes of Health, National Institute of Child and Human Development - N01-HD-3-3162
Amount: $5,010,161
Term: 2002-2007

Demonstration Project to Improve Research and Care of HIV-Infected Children
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Department of Health and Human Services, Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: $4,437,722
Term: 1995-2004

Expansion of Pediatric ACTU
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - U0132915-05
Amount: $4,156,500
Term: 1996-2007

Demonstration Project to Improve Research and Care of HIV-Infected Children
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Elizabeth J. McFarland, MD
Source: Health Resources and Services Administration, Ryan White Title IV HIV Program
Amount: $2,507,595
Term: 2001-2004

Trial of Varicella Vaccine for the Prevention of Herpes Zoster and its Complications
Principal Investigator: Myron J. Levin, MD
Source: National Institute of Allergy and Infectious Disease, Veterans Administration - VA CSP403
Amount: $1,532,185
Term: 1998-2004

Depression and Trial of Varicella Vaccine in the Elderly
Principal Investigator: Myron J. Levin, MD
Source: UCLA Medical Center
Amount: $388,001
Term: 2000-2004

Probe Study to Evaluate the Safety, Tolerability and Immunogenicity of a Process Upgrade Varicella-Zoster Vaccine as a Booster Dose in Previously Vaccinated Adults 60 Years of Age and Older
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Zoster Protocol 005
Amount: $132,000
Term: 1999-2004

Pediatric HIV Clinical Trials Network
Principal Investigator: Myron J. Levin, MD
Co-Investigator: Mark J. Abzug, MD
Source: National Institutes of Health, National Institute of Child Health and Human Development - N01-HD-3-3162
Amount: $117,875
Term: 2002-2004

A Phase III, Open-Labeled, Randomized, Multicenter, Clinical Study of the Safety of a Primary Series of GlaxoSmithKline Biologicals' DTPa-HepB-IPV Candidate Vaccine Coadministered with HibTITER® and Prevnar® to Healthy Infants at 2, 4, and 6 Months of Age as Compared to the Separate Administration of Infanrix® + Engerix-B® + IPOL® + HibTITER® + Prevnar®
Principal Investigator: Myron J. Levin, MD
Source: GlaxoSmithKline Biologicals - 084
Amount: $111,678
Term: 2001-2003

Retrospective Study That Would Evaluate Asthmatic Children Who Had Already Received Varivax® in the Past
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories
Amount: $69,000
Term: 2003-2006

A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety, Tolerability and Immunogenicity After One and Two Doses of PHN/Zoster Vaccine
Principal Investigator: Myron J. Levin, MD
Source: Merck Research Laboratories - Zoster Protocol 007
Amount: $54,900
Term: 2001-2004

Phospholipases in the Pathogenesis of Mycobacterium Tuberculosis
Principal Investigator: Sarah K. Parker, MD
Source: National Institutes of Health - 1 K08 AI050646-04
Amount: $560,000
Term: 2002-2007

CD40-CD154 Interactions in Cryptosporidial Immunity
Principal Investigator: Esther Ponnuraj, PhD
Source: National Institutes of Health - R01 A140870-05
Amount: $673,622
Term: 2002-2005

Respiratory Viral Infections in Filipino Children
Principal Investigator: Eric A. F. Simoes, MD
Co-Investigator: Adriana Weinberg, MD
Source: World Health Organization
Amount: $170,000
Term: 2001-2004

Immunogenicity of Influenza Vaccine in Children with Rheumatologic Disorders
Principal Investigator: Jennifer Soep, MD
Co-Investigator: Adriana Weinberg, MD
Source: Pediatric General Clinical Research Center
Amount: $10,000
Term: 2001-2003

Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Co-Principal Investigators: Harley A. Rotbart, MD, and Mark J. Abzug, MD
Co-Investigator: Joseph D. Spahn, MD
Source: National Institutes of Health, National Institute of Childhood Health and Disease - HD37237
Amount: $1,364,175
Term: 1999-2003

Pediatric AIDS Clinical Trials Group
Principal Investigator: Adriana Weinberg, MD
Source: National Institute of Childhood Diseases - N01-HD-33162
Amount: $1,796,322
Term: 1997-2003

Shingles Prevention Study
Principal Investigator: Adriana Weinberg, MD
Source: Veterans Administration - CSP403
Amount: $960,642
Term: 2001-2004

Immune Responses to Varicella Vaccine in HIV-Infected Adults
Principal Investigator: Kathleen Brady, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - K23RR16116-02
Amount: $754,246
Term: 2000-2005

Epidemiology of Adult Glioma
Principal Investigator: Margaret Wrensch, MD
Co-Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - R01 CA52689
Amount: $8,000,863
Term: 2001-2006

Manufacturing of VZV Antigen
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $280,000
Term: 1999-2004

VZV ELISPOT Validation for Studies of VZV-Specific Cell-Mediated Immunity
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $224,125
Term: 2001-2004

CMV Immune Reconstruction in AIDS Patients on HAART
Principal Investigator: Adriana Weinberg, MD
Source: National Institutes of Health - 2U01A38858 AACTG 360.06
Amount: $152,000
Term: 2002-2003

Persistence of VZV Immunity in Elderly Recipients of the PHN/Zoster Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $49,000
Term: 2001-2004

Cell-Mediated Immunity in Herpes Zoster Patients
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $48,000
Term: 2001-2004

Kinetics of Cell-Mediated Immune Responses to PHN/Zoster Vaccine
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $46,626
Term: 2001-2004

Diagnosis of CMV Infection in Stem Cell Recipients
Principal Investigator: Adriana Weinberg, MD
Source: AmCell
Amount: $20,000
Term: 2002-2004

PCR Diagnosis of Zoster
Principal Investigator: Adriana Weinberg, MD
Source: Merck Research Laboratories
Amount: $15,000
Term: 2001-2003

Evaluation of Directigen EZ Flu A+B Kit
Principal Investigator: Adriana Weinberg, MD
Source: Becton Dickinson
Amount: $10,000
Term: 2002-2003

Flu OIA Evaluation
Principal Investigator: Adriana Weinberg, MD
Source: Biostar
Amount: $10,000
Term: 2002-2003

Head CT in the Evaluation of 1st Afebrile Seizures
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, Louis C. Hampers, MD, MBA, Carol Okada, MD, and Rebecca Fastle, MD
Term: 2000-2004

Postreduction Management of Intussusception
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, and Shayne Bland, MSc
Term: 2000-2002

Emergency Medical Services for Children Partnership Grant
Principal Investigator: F. Keith Battan, MD
Source: US Department of Health and Human Services, Maternal and Child Health Bureau -
FLAEMS01-00250
Amount: $122,000
Term: 2000-2001

L.O.C.O. (Latinos Overcoming Cultural Obstacles) "Needs Assessment for The Children's Hospital"
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001

The Truth about Language Barriers
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Stephen Federico, MD
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001-ongoing

Jungle Mobile: A Mobile Injury Prevention Project for Children
Principal Investigator: Kathryn D. Emery, MD
Co-Investigators: Allison Hawkes, MD, MS, Theresa Rapstine, RN, and Victoria Cassenbaugh, RN
Term: 1998-ongoing

A Screening Tool for the Detection of Child Abuse in the Emergency Department Setting
Joint Project with the Child Advocacy Protection Team

Principal Investigator: Kathryn D. Emery, MD
Term: 2001

Seat Belt and Car Safety Seat Use in SUVs
Primary Investigator: Kathryn D. Emery, MD
Co-Investigators: Lisa Hardin Van Bramer, MD, and Kevin Raines, MD
Source: National Highway Traffic Safety Administration - STNH22-01-H-05-257
Amount: $350,000
Term: 2001-2003

Childhood Injury Prevention Concerns of Migrant and Seasonal Farm Workers in Weld County
Principle Investigator: Kathryn D. Emery, MD
Co-Investigator: S. Glenn Faries, MD
Source: Colorado Injury Control Research Center
Amount: $15,000
Term: 2002-2003

Domestic Violence Policies in Pediatric Emergency Departments
Principle Investigator: Kathryn D. Emery, MD
Co-Investigators: Sheila Sullivan, MD, Andrew P. Sirotnak, MD, and Stephanie Stronks-Knapp, MD
Term: 2002-ongoing

Development of an Injury-Free Coalition for Kids
Principal Investigator: S. Glenn Faries, MD
Co-Investigator: Kathryn D. Emery, MD
Term: 2001-ongoing

Resident Education in the Emergency Department
Principal Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Need for Atropine for Emergent Pediatric Intubations
Principal Investigator: Rebecca Fastle, MD
Co-Investigator: Mark G. Roback, MD
Term: 1999-ongoing

Resuscitation Teaching at Primary Care Centers
Principal Investigator: Margaret Ferguson, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-ongoing

Utility of Anaerobic Blood Cultures in a Pediatric Emergency Department
Principal Investigator: Stephen Freedman, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2003

PEM Collaborative Research Committee, Cerebral Edema and DKA
Principal Investigator: Nicole Glaser, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-2001

Comparison of Oral Prednisone vs. Dexamethasone in Pediatric Asthma
Principal Investigator: Richard A. Greenberg, MD
Co-Investigators: Genie E. Roosevelt, MD, MPH, and Gwendolyn S. Kerby, MD
Term: 2002-ongoing

Peak Flow vs. Spirometry in Acute Asthma
Principal Investigator: David Gutglass, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 1997-ongoing

A.C.C.E.S.S. for Latinos: After-Hours Call Center and Extended Spanish Service
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: Lauren Clark, PhD, RN, and Stephen Berman, MD
Term: 2001-2002

The Impact of Interpreters on Resource Utilization in a Pediatric Emergency Department
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Jennifer McNulty, MD
Term: 1999-2002

Physician-Based Practice Pattern Variations in the Management of AGE
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Elizabeth Powell, MD, MPH
Term: 2001-ongoing

Practice Variation in the Management of Croup
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 1999-2002

Regional After-Hours Urgent Care Provided by a Tertiary Children's Hospital
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 2001-2002

Booster Seat Project
Principal Investigator: Lisa Hardin Van Bramer, MD
Co-Investigator: Kathryn D. Emery, MD
Source: Emergency Medical Services and Kiwanis Pediatric Trauma Institute
Amount: $18,000
Term: 2001-2002

Association of Influenza with Bacterial Tracheitis
Principal Investigator: Ron L. Kaplan, MD
Co-Investigators: Mark G. Roback, MD, and Peggy Kelly, MD
Term: 2002-ongoing

Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Patients Birth to 48 Months Old with Reactive Airways Disease in an Acute Setting
Principal Investigator: Gwendolyn S. Kerby, MD
Co-Investigator: S. Glenn Faries, MD
Term: 2001-2002

Effect of Ondansetron on Ketamine Sedation-Associated Vomiting
Principal Investigator: William T. Langston, MD
Co-Investigators: Joseph E. Wathen, MD, and Mark G. Roback, MD
Source: The Children's Hospital Research Institute
Amount: $5,000
Term: 2002-ongoing

Effect of Medical Spanish Classes on Satisfaction of Hispanic Patients in Pediatric Emergency Department
Principal Investigator: Suzanne Mazor, MD
Co-Investigators: Vidya Chande, MD, Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 2000-2002

Interpretation of Traumatic Lumbar Punctures: Who Can Go Home?
Principal Investigator: Suzan Mazor, MD
Co-Investigators: Jennifer McNulty, MD, and Genie E. Roosevelt, MD, MPH
Term: 2001-ongoing

How Is Emergency Department Decision-Making Affected by the Existence of Reliable Follow-Up?
Principal Investigator: Jennifer McNulty, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 1999-2001

Decision Rules for Obtaining Radiographs in Pediatric Knee Injuries
Principal Investigator: Brian Moore, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Kathryn Emery, MD
Term: 1998-ongoing

Indications for Knee Radiographs in Pediatric Patients with Acute Knee Injuries/Validation of a Clinical Decision Rule
Principal Investigator: Brian Moore, MD
Co-Investigators: Carol Turner, MD, and Kathryn D. Emery, MD
Term: 2000-ongoing

Correlation of Hemolysis with Facticous Hyperkalemia
Principal Investigator: Heather Owens, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Acute Complication of Type 1 Diabetes in Children
Primary Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Mark G. Roback, MD, and Joan P. Bothner, MD
Term: 2001-ongoing

Childhood Pedestrian Injuries
Primary Investigator: Arleta B. Rewers, MD, PhD
Term: 2002-ongoing

Femur Fractures and Associated Injuries
Principal Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Kathryn D. Emery, MD, and F. Keith Battan, MD
Term: 2000-ongoing

Are Chest X-Rays Required for all First-Time Wheezers?
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Mark E. Anderson, MD, and John D. Strain, MD
Term: 1998-ongoing

Comparison of the Efficacy and Safety of Sedation Drugs Used in a Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Joseph E. Wathen, MD, and Joan P. Bothner, MD
Term: 1999-ongoing

IV vs. IM Ketamine Sedation in the Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Joseph E. Wathen, MD
Source: The Children's Hospital Research Institute
Amount: $35,000
Term: 2000-ongoing

Pediatric Resuscitation Practice and Success Rate
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Rebecca Fastle, MD
Term: 2000-ongoing

Predictors of Which Patients will Benefit from Observations vs. Hospital Admission
Principal Investigator: Genie E. Roosevelt, MD, MPH
Co-Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Randomized, Double-Blind Study of Intravenous Fluids With and Without Dextrose in the Treatment of Dehydration in Pediatric Patients with Vomiting and Ketosis
Principal Investigator: Genie E. Roosevelt, MD, MPH
Term: 2002-ongoing

The Effect of Dehydration on the QT Interval of Healthy Children
Principal Investigator: Carl Shaw, MD
Co-Investigators: Joseph E. Wathen, MD, and Michael S. Schaffer, MD
Term: 2001

The Prevalence of Urinary Tract Infections in Febrile Children with AGE
Principal Investigator: Carl Shaw, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Use of Complementary Medicine in Pediatric Patients with Asthma
Principal Investigator: Alison Siegel Tothy, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2002

Associations between Insurance Type and Pediatric Admission Rate in Colorado, 1993-1999: Is Managed Care Fulfilling Its Promise?
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and James K. Todd, MD
Term: 2000-ongoing

Associations of Parental Depression and Child Health Outcomes
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Allison Kempe, MD, John Steiner, MD, David Price, MD, and David Magid, MD
Term: 2002-ongoing

Comparison of the Longitudinal Marginal Cost, Morbidity and Mortality of Inflicted and Unintentional Head Injuries in Young Children in a Nationwide Sample of Children's Hospitals
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Costs of Childhood Physical Abuse: Comparing Inflicted and Unintentional Head Injuries in Colorado Inpatients Under Three Years Old
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Epidemiology of Pediatric Psychiatric Visits to US Emergency Departments, Based on the National Hospital Ambulatory Medical Care Survey 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Hospital-Level Predictors of Inefficiency Amongst Hospitalized Patients in New York State
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and Andrew Racine, MD, PhD
Term: 2000-ongoing

Management of Acute Gastroenteritis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Management of Bronchiolitis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1993-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Comparison of Fascia Iliaca Compartment Nerve Block to Traditional Systemic Analgesics for Femur Fractures in a Pediatric Emergency Department
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Glen Merritt, MD, Gaia Georgopoulos, MD, and F. Keith Battan, MD
Source: The Children's Hospital Research Institute
Amount: $17,594
Term: 2001-2004

Pediatric EKG Interpretation Accuracy by Pediatric Emergency Medicine Physicians
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Arleta Rewers, MD, PhD, Angela Yetman MD, and Michael Schaffer MD
Term: 2001-ongoing

A Randomized Trial of Telephonic vs. On-Site Language Interpretation in a Pediatric ED
Principal Investigator: Ethan S. Wiener, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing